Pilgaardpetersson1990

Landmarks from the voyage: The tale regarding refugees turning out to be Rn's australia wide.

in English, German EINLEITUNG Ein substanzieller Teil der aktuellen Literatur zur COVID-19-Pandemie beschäftigt sich mit deren ophthalmologischen Aspekten. In diesem Übersichtsartikel soll ein Überblick über die bisher publizierten Studien gegeben werden, die für die Ophthalmologie relevant sind. MATERIAL UND METHODEN PubMed.gov wurde systematisch nach Artikeln mit den folgenden Schlüsselwörtern durchsucht „COVID-19“, „Coronavirus“ und „SARS‐CoV‐2“ in Verbindung mit „Ophthalmology“ und „Eye“. Darüber hinaus wurde eine Analyse der Empfehlungen der ophthalmologischen Fachgesellschaften durchgeführt, insbesondere der American Academy of Ophthalmology (AAO) und des Royal College of Ophthalmologists (RCOphth). ERGEBNISSE Es wurden 21 Artikel mit Peer Review zu den ophthalmologischen Aspekten von COVID-19 identifiziert (Stand 16. April 2020). Davon stammten 12 (57,1%) aus Asien, 6 (28,6%) aus den Vereinigten Staaten und 3 (14,3%) aus Europa. Darunter befanden sich 5 Originalarbeiten (23,8%), 10 (47,6%) Briefe an den Herausgeber, 3 (14,2%) Fallberichte und 3 (14,2%) Übersichtsartikel. Es erfolgte eine Sortierung in folgende Themen „(Okuläre) Übertragungswege und Prävention“, „Ophthalmologische Manifestation von COVID-19“, „Klinische Richtlinien für die ophthalmologische Praxis während der COVID-19-Pandemie“ und „Praktische Empfehlungen für den klinischen Alltag“. Letztere wurden den Empfehlungen der AAO und des RCOphth entnommen. SCHLUSSFOLGERUNGEN Eine Vielzahl kürzlich erschienener Artikel befasst sich mit den ophthalmologischen Aspekten von COVID-19. Da COVID-19 über das Auge übertragen werden kann (aktiv über die Tränenflüssigkeit und passiv über den Ductus nasolacrimalis), ist eine sorgfältige Infektionsprävention in der ophthalmologischen Praxis von großer Bedeutung. Eine Augenbeteiligung kann sich als Keratokonjunktivitis manifestieren.Cardiovascular disease, including stroke, myocardial infarction, and venous thromboembolism, is one of the leading causes of morbidity and mortality worldwide. Excessive coagulation may cause vascular occlusion in arteries and veins eventually leading to thrombotic diseases. Studies in recent years suggest that coagulation factors are involved in these pathological mechanisms. Factors XIa (FXIa), XIIa (FXIIa), and plasma kallikrein (PKa) of the contact system of coagulation appear to contribute to thrombosis while playing a limited role in hemostasis. Contact activation is initiated upon autoactivation of FXII on negatively charged surfaces. FXIIa activates plasma prekallikrein (PK) to PKa, which in turn activates FXII and initiates the kallikrein-kinin pathway. FXI is also activated by FXIIa, leading to activation of FIX and finally to thrombin formation, which in turn activates FXI in an amplification loop. Animal studies have shown that arterial and venous thrombosis can be reduced by the inhibition of FXI(a) or PKa. Furthermore, data from human studies suggest that these enzymes may be valuable targets to reduce thrombosis risk. In this review, we discuss the structure and function of FXI(a) and PK(a), their involvement in the development of venous and arterial thrombosis in animal models and human studies, and current therapeutic strategies. Georg Thieme Verlag KG Stuttgart · New York.BACKGROUND  The electronic health record (EHR) has historically been known to be a source of stress and dissatisfaction, leading to reduced efficiency and productivity for providers. This issue is complicated by constant changes in EHRs that are necessary to keep systems current with evolving functionality. Knowing the existence of this problem, an evidenced-based solution, known as an efficiency workshop, was developed by our information technology training and optimization team for providers as a means of ongoing professional development. OBJECTIVES  The objectives of this project were to identify EHR optimization needs for providers in various clinical departments and improve their EHR satisfaction. Cyclopamine manufacturer The development of a program focused on provider efficiency tools and personalization was key and, once piloted, how to measure program success. METHODS  Efficiency workshops comprised members of the IT training team who set up on site training sessions during reserved time with providers during departmental meetings. Sessions focused on reviewing EHR efficiency tools using demonstration of existing system functionality. Participating providers were given continuing medical education (CME) credits upon completion of evaluations used as a quality improvement tool for the program. RESULTS  Descriptive results showed that providers were satisfied with this method of EHR instruction. Subjective feedback yielded positive themes such as informative, well done, organized, and helpful. Cyclopamine manufacturer CONCLUSION  This initiative began as a pilot program and successfully expanded across clinical departments at our academic medical center. Future plans are to sustain and further invest in this program by using EHR reporting features to further customize these sessions and evaluate impact on system use. Georg Thieme Verlag KG Stuttgart · New York.BACKGROUND  Increased use of health information technology (HIT) has been advocated as a medication error reduction strategy. Evidence of its benefits in the pediatric setting remains limited. In 2012, electronic prescribing (ICCA, Philips, United Kingdom) and standard concentration infusions (SCIs)-facilitated by smart-pump technology-were introduced into the pediatric intensive care unit (PICU) of an Irish tertiary-care pediatric hospital. OBJECTIVE  The aim of this study is to assess the impact of the new technology on the rate and severity of PICU prescribing errors and identify technology-generated errors. METHODS  A retrospective, before and after study design, was employed. Medication orders were reviewed over 24 weeks distributed across four time periods preimplementation (Epoch 1); postimplementation of SCIs (Epoch 2); immediate postimplementation of electronic prescribing (Epoch 3); and 1 year postimplementation (Epoch 4). Only orders reviewed by a clinical pharmacist were included. Prespecified definitions, multidisciplinary consensus and validated grading methods were utilized.